Document is current
Any future updates will be listed below
-
Authors
Wensink, G. Emerens https://orcid.org/0000-0002-4103-5811
Elias, Sjoerd G.
Mullenders, Jasper
Koopman, Miriam
Boj, Sylvia F.
Kranenburg, Onno W.
Roodhart, Jeanine M. L. https://orcid.org/0000-0003-1398-8970
- License Information
-
More Information
Article History
Received: 28 October 2020
Accepted: 10 March 2021
First Online: 12 April 2021
Competing interests
: S.F.B. is inventor on patents related to the Organoid Technology. S.F.B. and J.M. are employed by the Foundation Hubrecht Organoid Technology (HUB). The remaining authors declare no conflict of interest. M.K. Institutional financial instructs (IFI): Amgen, Bayer, BMS, Merck-Serono, Nordic Farma, Roche, Servier, Sirtex, Sanofi-Aventis; O.W.K. IFI: Genmab, Johnson & Johnson; J.M.L.R. IFI: Servier, Merck, Bayer. All grants were unrelated to the study and paid to the individual’s institution. All authors are involved in an ongoing prospective clinical trial evaluating the predictive role of organoids in mCRC patients.
